



3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)

GLOBAL OFFERING

- Number of Offer Shares under the Global Offering : 16,350,000 Shares (subject to the Over-allotment Option)
- Number of Hong Kong Offer Shares : 1,635,000 Shares (subject to reallocation)
- Number of International Offer Shares : 14,715,000 Shares (subject to reallocation and the Over-allotment Option)
- Maximum Offer Price : HK\$26.24 per Offer Share, plus brokerage of 1%, AFRC transaction levy of 0.00015%, SFC transaction levy of 0.0027%, and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund)
- Nominal value : HK\$0.001 per Share
- Stock code : 1244

全球發售

- 全球發售的發售股份數目 : 16,350,000股股份 (視乎超額配股權行使與否而定)
- 香港發售股份數目 : 1,635,000股股份 (可予重新分配)
- 國際發售股份數目 : 14,715,000股股份 (可予重新分配及視乎超額配股權行使與否而定)
- 最高發售價 : 每股發售股份26.24港元，另加1%經紀佣金、0.00015%會財局交易徵費、0.0027%證監會交易徵費及0.005%聯交所交易費 (須於申請時以港元繳足，多繳股款可予退還)
- 面值 : 每股股份0.001港元
- 股份代號 : 1244

Application Form 申請表格

Please read carefully the prospectus of 3D Medicines Inc. (the "Company") dated November 29, 2022 (the "Prospectus") (in particular, the section headed "How to Apply for Hong Kong Offer Shares" in the Prospectus) and the guidelines on the back of this Application Form before completing this Application Form. Terms used in this Application Form shall have the same meanings as those defined in the Prospectus unless defined herein.

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), Hong Kong Securities Clearing Company Limited ("HKSCC"), the Securities and Futures Commission of Hong Kong ("SFC") and the Registrar of Companies in Hong Kong take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of this Application Form.

A copy of this Application Form, the Prospectus and the other documents specified in the section headed "Appendix V – Documents Delivered to the Registrar of Companies and Available on Display" to the Prospectus have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The SFC and the Registrar of Companies in Hong Kong take no responsibility as to the contents of any of these documents.

Your attention is drawn to the paragraph headed "Personal Information Collection Statement" which sets out the policies and practices of the Company and the Hong Kong Branch Share Registrar in relation to personal data and compliance with the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong).

Nothing in this Application Form or the Prospectus constitutes an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This Application Form and the Prospectus are not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This Application Form and the Prospectus do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be registered under the United States Securities Act of 1933 as amended (the "U.S. Securities Act") or securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or transferred within the United States, except that Offer Shares may be offered, sold or delivered (a) in the United States solely to qualified institutional buyers in reliance on Rule 144A or another exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act or (b) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in whole or in part) in any manner whatsoever in any jurisdiction where such forwarding, distribution or reproduction is not permitted under the law of that jurisdiction. This Application Form and the Prospectus are addressed to you personally. Any forwarding or distribution or reproduction of this Application Form or the Prospectus in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the U.S. Securities Act or the applicable laws of other jurisdictions.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation as described in the section headed "Structure of the Global Offering" in the Prospectus. In particular, the Joint Representatives may reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Guidance Letter HKEX-GL91-18 issued by the Stock Exchange, if such reallocation is done other than pursuant to clawback mechanism as described in the section headed "Structure of the Global Offering – The Hong Kong Public Offering – Reallocation" in the Prospectus, then the maximum number of the Offer Shares available under the Hong Kong Public Offering after any such reallocation shall not exceed 3,270,000 Offer Shares, representing 20% of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), and the final Offer Price shall be fixed at HK\$22.96 per Offer Share (being the low-end of the Offer Price range stated in the Prospectus).

If the number of Offer Shares validly applied for in the Hong Kong Public Offering represents (i) 15 times or more but less than 50 times, (ii) 50 times or more but less than 100 times, and (iii) 100 times or more, of the number of Hong Kong Offer Shares available under the Hong Kong Public Offering, the total number of Hong Kong Offer Shares available under the Hong Kong Public Offering will be increased to 4,905,000 Shares (in the case of (i)), 6,540,000 Shares (in the case of (ii)), and 8,175,000 Shares (in the case of (iii)), respectively, representing 30%, 40% and 50% of the total number of Offer Shares initially available under the Global Offering, respectively (before any exercise of the Over-allotment Option). Further details of the reallocation are stated in the section headed "Structure of the Global Offering – The Hong Kong Public Offering – Reallocation" of the Prospectus.

- To: 3D Medicines Inc.
- Joint Sponsors
- Joint Representatives
- Joint Global Coordinators
- Joint Bookrunners
- Joint Lead Managers
- Hong Kong Underwriters

在填寫本申請表格前，請細閱3D Medicines Inc. (「本公司」)日期為2022年11月29日的招股章程(「招股章程」)(尤其是招股章程「如何申請香港發售股份」一節)及本申請表格背面的指引。除本申請表格另有界定者外，本申請表格所用詞彙與招股章程所界定者具有相同涵義。

香港交易及結算所有限公司、香港聯合交易所有限公司(「聯交所」)、香港中央結算有限公司(「香港結算」)、香港證券及期貨事務監察委員會(「證監會」)及香港公司註冊處處長對本申請表格的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就此本申請表格全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。

本申請表格、招股章程及招股章程「附錄五 – 送呈公司註冊處處長及展示文件」一節所列的其他文件副本已根據香港法例第32章公司(清盤及雜項條文)條例第342C條的規定送呈香港公司註冊處處長登記。證監會及香港公司註冊處處長對任何該等文件的內容概不負責。

閣下請留意「個人資料收集聲明」一段，當中載有本公司及香港證券登記分處就個人資料及遵守香港法例第486章《個人資料(私隱)條例》制定的政策及慣例。

本申請表格或招股章程內容並不構成出售要約或要約購買的遊說，亦不得在進行有關要約、遊說或出售屬違法的任何司法權區出售任何發售股份。本申請表格及招股章程不會直接或間接於或向美國(包括其領土及屬地、美國任何州以及哥倫比亞特區)發佈、刊發或分派。本申請表格及招股章程並不構成在美國境內或任何其他司法權區購買或認購證券的要約或邀請或其組成部分。發售股份並未且不會根據1933年美國《證券法》(經修訂)(「美國《證券法》」)或美國任何州或其他司法權區的證券法登記，且不會於美國境內提呈發售、出售、抵押或轉讓，惟發售股份可(a)在美國根據美國《證券法》的登記豁免或在毋須遵守美國《證券法》登記規定的交易中向合格機構買家(定義見第144A條)或(b)根據美國《證券法》項下的S規例以離岸交易方式於美國境外提呈發售、出售或交付。

在任何根據有關司法權區法律不得發送、派發或複製本申請表格及招股章程的司法權區內，本申請表格及招股章程概不得以任何方式發送或派發或複製(全部或部分)。本申請表格及招股章程僅致予閣下本人。概不得發送或派發或複製本申請表格或招股章程的全部或部分。如未能遵守此項指令，可能違反美國證券法或其他司法權區的適用法律。

香港公開發售與國際發售之間的發售股份分配將按招股章程「全球發售的架構」一節所述予以重新分配。尤其是，聯席代表可能將發售股份由國際發售重新分配至香港公開發售，以滿足香港公開發售的有效申請。根據聯交所頒佈的指引信HKEX-GL91-18，倘該重新分配並非按招股章程「全球發售的架構 – 香港公開發售 – 重新分配」一節所述回補機制作出，於任何有關重新分配後，香港公開發售項下可供認購的發售股份的最高數目不得超過3,270,000股發售股份，佔全球發售下初步可供認購發售股份的20%(行使任何超額配股權前)，且最終發售價將釐定為每股發售股份22.96港元，即招股章程所述發售價範圍的下限。

倘香港公開發售有效申請的發售股份數目等於香港公開發售可供認購的香港發售股份數目的(i) 15倍或以上但少於50倍；(ii) 50倍或以上但少於100倍；及(iii) 100倍或以上，則香港公開發售可供認購的香港發售股份總數將分別增至4,905,000股股份、如屬(ii)的情況、6,540,000股股份(如屬(i)的情況)及8,175,000股股份(如屬(iii)的情況)，分別相當於全球發售初步可供認購發售股份總數的30%、40%及50%(任何超額配股權行使前)。有關重新分配的進一步詳情載於招股章程「全球發售的架構 – 香港公開發售 – 重新分配」一節。

- 致： 3D Medicines Inc.
- 聯席保薦人
- 聯席代表
- 聯席全球協調人
- 聯席賬務經理人
- 聯席牽頭經辦人
- 香港包銷商

We confirm that we have (i) complied with the Guidelines for Electronic Public Offerings and the Operational Procedures for HK eIPO White Form Applications submitted via banks/stock brokers and all applicable laws and regulations (whether statutory or otherwise) in relation to the provision of our HK eIPO White Form services in connection with the Hong Kong Public Offering; and (ii) read the terms and conditions and application procedures set out in the Prospectus and this Application Form and agree to be bound by them. Applying on behalf of each of the underlying applicants to whom this application relates, we:

- apply for the number of Hong Kong Offer Shares set out below, on the terms and conditions of the Prospectus and this Application Form, and subject to the Memorandum and the Articles of Association;
- enclose payment in full for the Hong Kong Offer Shares applied for, including brokerage of 1.0%, AFRC transaction levy of 0.00015%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%;
- confirm that the underlying applicants have undertaken and agreed to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to such underlying applicants on this application;
- undertake and confirm that the underlying applicant(s) and the person for whose benefit the underlying applicant(s) is/are applying has/have not applied for, or indicated an interest for, or received or been placed or allocated (including conditionally and/or provisionally), and will not apply for or take up, or indicate an interest for, any Offer Shares under the International Offering nor otherwise participate in the International Offering;
- understand that these declarations and representations will be relied upon by the Company and the Joint Representatives in deciding whether or not to make any allotment of Hong Kong Offer Shares in response to this application;
- authorize the Company to place the name(s) of the underlying applicant(s) on the register of members of the Company as the holder(s) of any Hong Kong Offer Shares to be allotted to them, and (subject to the terms and conditions set out in this Application Form) to send any Share certificate(s) and/or e-Auto Refund payment instructions (where applicable) and/or any refund cheque(s) (where applicable) by ordinary post at that underlying applicant's own risk to the address specified in the application instruction(s) of the underlying applicant(s) in accordance with the procedures prescribed in this Application Form, the IPO App, the designated website of HK eIPO White Form Service Provider at www.hkeipo.hk and in the Prospectus;
- request that any e-Auto Refund payment instructions be despatched to the application payment bank account where the applicant has paid the application monies from a single bank account;
- request that any refund cheque(s) be made payable to the underlying applicant(s) who has used multiple bank accounts to pay the application monies and to send any such refund cheque(s) by ordinary post at that underlying applicant's own risk to the address stated on the application in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- confirm that each underlying applicant has read the terms and conditions and application procedures set out in this Application Form, in the IPO App and on the designated website of HK eIPO White Form Service Provider at www.hkeipo.hk, and in the Prospectus and agrees to be bound by them;
- represent, warrant and undertake (a) that the underlying applicant(s) and any persons for whose benefit the underlying applicant(s) is/are applying is not restricted by any applicable laws of Hong Kong or elsewhere from making this application, paying any application monies for, or being allocated or taking up, any Hong Kong Offer Shares; and (b) that the allocation of or application for the Hong Kong Offer Shares to the underlying applicant or by underlying applicant or for whose benefit this application is made would not require the Company, Joint Sponsors, Joint Representatives, Joint Global Coordinators, Joint Bookrunners, Joint Lead Managers and the Hong Kong Underwriters or their respective officers or advisers to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong; and
- agree that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong.

吾等確認，吾等已(i)遵守電子公開發售指引及透過銀行/股票經紀遞交網上白表申請的運作程序以及與吾等有關香港公開發售提供網上白表服務有關的所有適用法例及規例(不論法定或其他)；及(ii)細閱招股章程及本申請表格所載的條款及條件以及申請手續，並同意受其約束。為代表與本申請有關的每名相關申請人作出承諾，吾等：

- 按照招股章程及本申請表格的條款及條件，並在組織章程大綱及細則的規限下，申請以下數目的香港發售股份；
- 隨附申請香港發售股份所需的全數付款(包括1.0%經紀佣金、0.00015%會財局交易徵費、0.0027%證監會交易徵費及0.005%聯交所交易費)；
- 確認相關申請人已承諾及同意接納所申請的香港發售股份，或彼等根據本申請獲分配的任何較少數目香港發售股份；
- 承諾及確認相關申請人及相關申請人為其利益而提出申請的人士並無申請或認購或表示有意認購或收買或獲配或分配(包括有條件及/或暫定)，並將不會申請或認購或表示有意認購國際發售的任何發售股份，亦不會以其他方式參與國際發售；
- 明白 貴公司及聯席代表將依賴此等聲明及陳述決定是否就是項申請配發任何香港發售股份；
- 授權 貴公司將相關申請人的姓名/名稱列入 貴公司股東名冊內，作為將配發予相關申請人的任何香港發售股份的持有人，並(在符合本申請表格所載的條款及條件的情況下)根據本申請表格、IPO App、網上白表服務供應商指定網站www.hkeipo.hk以及招股章程所規定程序按相關申請人的申請指示所指定的地址以普通郵遞方式寄發任何股票及/或電子自動退款指示(如適用)及/或任何退款支票(如適用)，郵誤風險概由該相關申請人承擔；
- 要求將任何電子自動退款指示發送到申請人以單一銀行賬戶繳交申請股款的申請付款銀行賬戶內；
- 要求任何以多個銀行賬戶繳交申請股款的申請人的退款支票以相關申請人為抬頭人，並根據本申請表格及招股章程所述程序將任何有關退款支票以普通郵遞方式寄發到申請所列的地址，郵誤風險概由該相關申請人承擔；
- 確認各相關申請人已細閱本申請表格、IPO App、網上白表服務供應商指定網站(www.hkeipo.hk)及招股章程所載的條款及條件以及申請手續，並同意受其約束；
- 聲明、保證及承諾(a)相關申請人及相關申請人為其利益提出申請的任何人士並不受香港或其他地方之任何適用法律限制提出本申請、支付任何申請股款或獲分配或承購任何香港發售股份；及(b)向相關申請人或由相關申請人或為其利益而提出本申請的人士分配或申請認購香港發售股份，不會引致 貴公司、聯席保薦人、聯席代表、聯席全球協調人、聯席賬務經理人、聯席牽頭經辦人及香港包銷商或被等各自的高級職員或顧問須遵從香港以外任何地區的任何法律或規例(不論是否具法律效力)的任何規定；及
- 同意本申請、對本申請的任何接納及據此訂立的合約將受香港法例管轄及按其詮釋。

Signature 簽名	
Name of applicant 申請人姓名	

Date 日期	
Capacity 身份	

We, on behalf of the underlying applicants, offer to purchase 吾等(代表相關申請人)提出認購	Total number of Hong Kong Offer Shares 香港發售股份總數
---	--

Hong Kong Offer Shares on behalf of the underlying applicants whose details are contained in the read-only CD-ROM submitted with this Application Form.
代表相關申請人提出認購的香港發售股份(申請人的詳細資料載於連同本申請表格遞交的唯讀光碟)。

A total of 隨附合共	cheque(s) 張支票	Cheque Number(s) 支票號碼
are enclosed for a total sum of 總金額為	HKS	Name of Bank 銀行名稱
	港元	

Please use BLOCK letters 請用正楷填寫		
Name of HK eIPO White Form Service Provider 網上白表服務供應商名稱	HK eIPO White Form Service Provider ID 網上白表服務供應商編號	
Chinese name 中文名稱	Contact number 聯絡電話號碼	Fax number 傳真號碼
Name of contact person 聯絡人士姓名	For Broker use 此欄供經紀填寫 Lodged by 申請由以下經紀遞交	
Address 地址	Broker no. 經紀號碼	
	Broker's Chop 經紀印章	

For bank use 此欄供銀行填寫

GUIDELINES TO COMPLETING THIS APPLICATION FORM

References to boxes below are to the numbered boxes on this Application Form.

1 Sign and date the Application Form in Box 1. Only a written signature will be accepted.

The name and the representative capacity of the signatory should also be stated.

To apply for Hong Kong Offer Shares using this Application Form, you must be named in the list of **HK eIPO White Form Service Providers** who may provide **HK eIPO White Form** services in relation to the Hong Kong Public Offering, which was released by the SFC.

2 Put in Box 2 (in figures) the total number of Hong Kong Offer Shares for which you wish to apply on behalf of the underlying applicants.

Application details of the underlying applicants on whose behalf you are applying must be contained in one data file in read-only CD-ROM format submitted together with this Application Form.

3 Complete your payment details in Box 3.

You must state in this box the number of cheques you are enclosing together with this Application Form; and you must state on the reverse of each of those cheques (i) your **HK eIPO White Form Service Provider ID**; and (ii) the file number of the data file containing application details of the underlying applicant(s).

The dollar amount(s) stated in this box must be equal to the amount payable for the total number of Hong Kong Offer Shares applied for in Box 2. All cheque(s) and this Application Form together with a sealed envelope containing the CD-ROM, if any, must be placed in the envelope bearing your company chop.

For payments by cheque, the cheque must:

- be in Hong Kong dollars;
- not be post dated;
- be drawn on a Hong Kong dollar bank account in Hong Kong;
- show your (or your nominee's) account name;
- be made payable to "THE KA WAH BANK (NOMINEES) LIMITED – 3D MEDICINES INC PUBLIC OFFER";
- be crossed "Account Payee Only"; and
- be signed by the authorized signatories of the **HK eIPO White Form Service Provider**.

Your application may be rejected if any of these requirements is not met or if the cheque is dishonored on its first presentation.

It is your responsibility to ensure that details on the cheque(s) submitted correspond with the application details contained in the CD-ROM or data file submitted in respect of this application. The Company and the Joint Representatives have full discretion to reject any applications in the case of discrepancies.

No receipt will be issued for sums paid on application.

4 Insert your details in Box 4 (using BLOCK letters).

You should write the name, ID and address of the **HK eIPO White Form Service Provider** in this box. You should also include the name and telephone number of the contact person at your place of business and where applicable, the Broker No. and Broker's Chop.

Personal Information Collection Statement

This Personal Information Collection Statement informs the applicant for, and holder of, Hong Kong Offer Shares, of the policies and practices of the Company and the Hong Kong Branch Share Registrar in relation to personal data and the Personal Data (Privacy) Ordinance (Chapter 486 of the Laws of Hong Kong).

1 Reasons for the collection of your personal data

It is necessary for applicants and registered holders of the Hong Kong Offer Shares to supply correct personal data to the Company or its agents and the Hong Kong Branch Share Registrar when applying for the Hong Kong Offer Shares or transferring the Hong Kong Offer Shares into or out of their names or in procuring the services of the Hong Kong Branch Share Registrar.

Failure to supply the requested data may result in your application for the Hong Kong Offer Shares being rejected, or in delay or the inability of the Company or the Hong Kong Branch Share Registrar to effect transfers or otherwise render their services. It may also prevent or delay registration or transfers of the Hong Kong Offer Shares which you have successfully applied for and/or the dispatch of Share certificate(s) to which you are entitled.

It is important that the holders of the Hong Kong Offer Shares inform the Company and the Hong Kong Branch Share Registrar immediately of any inaccuracies in the personal data supplied.

2 Purposes

Your personal data may be used, held, processed, and/or stored (by whatever means) for the following purposes:

- processing your application and refund cheque and e-Auto Refund payment instruction(s), where applicable, verification of compliance with the terms and application procedures set out in this document and announcing results of allocation of the Hong Kong Offer Shares;
- compliance with all applicable laws and regulations in Hong Kong and elsewhere;
- registering new issues or transfers into or out of the names of the holders of the Shares including, where applicable, HKSCC Nominees;
- maintaining or updating the register of members of the Company;
- verifying identities of the holders of the Shares;
- establishing benefit entitlements of holders of the Shares, such as dividends, rights issues, bonus issues, etc.;
- distributing communications from the Company and its subsidiaries;
- compiling statistical information and profiles of the holder of the Shares;
- making disclosures as required by laws, rules or regulations;
- disclosing identities of successful applicants by way of press announcement(s) or otherwise;
- disclosing relevant information to facilitate claims on entitlements; and
- any other incidental or associated purposes relating to the above and/or to enable the Company and the Hong Kong Branch Share Registrar to discharge their obligations to holders of the Shares and/or regulators and/or any other purposes to which the holders of the Shares may from time to time agree.

3 Transfer of personal data

Personal data held by the Company and the Hong Kong Branch Share Registrar relating to the holders of the Hong Kong Offer Shares will be kept confidential but the Company and the Hong Kong Branch Share Registrar may, to the extent necessary for achieving any of the above purposes, disclose, obtain or transfer (whether within or outside Hong Kong) the personal data to, from or with any of the following:

- the Company's appointed agents such as financial advisers, receiving banks and overseas principal share registrar;
- where applicants for the Hong Kong Offer Shares request a deposit into CCASS, HKSCC or HKSCC Nominees, who will use the personal data for the purposes of operating CCASS;
- any agents, contractors or third-party service providers who offer administrative, telecommunications, computer, payment or other services to the Company or the Hong Kong Branch Share Registrar in connection with their respective business operation;
- the Hong Kong Stock Exchange, the SFC and any other statutory regulatory or governmental bodies or otherwise as required by laws, rules or regulations; and
- any other persons or institutions with which the holders of the Hong Kong Offer Shares have or propose to have dealings, such as their bankers, solicitors, accountants or stockbrokers etc.

4 Retention of personal data

The Company and the Hong Kong Branch Share Registrar will keep the personal data of the applicants and holders of the Hong Kong Offer Shares for as long as necessary to fulfil the purposes for which the personal data were collected. Personal data which is no longer required will be destroyed or dealt with in accordance with the Personal Data (Privacy) Ordinance.

5 Access and correction of personal data

The holders of the Hong Kong Offer Shares have the right to ascertain whether the Company or the Hong Kong Branch Share Registrar hold their personal data, to obtain a copy of that data, and to correct any data that is inaccurate. The Company and the Hong Kong Branch Share Registrar have the right to charge a reasonable fee for the processing of such requests. All requests for access to data or correction of data should be addressed to the Company and the Hong Kong Branch Share Registrar, at their registered address disclosed in the section headed "Corporate information" in the Prospectus or as notified from time to time, for the attention of the company secretary, or the Hong Kong Branch Share Registrar for the attention of the privacy compliance officer.

By signing an Application Form, you agree to all of the above.

DELIVERY OF THIS APPLICATION FORM

This completed Application Form, together with the appropriate cheque(s) together with a sealed envelope containing the CD-ROM, must be submitted to the following receiving bank by Wednesday, December 7, 2022 at 4:00 p.m.:

China CITIC Bank International Limited
4 Floor, Devon House, Taikoo Place
979 King's Road, Quarry Bay, Hong Kong

填寫本申請表格的指引

下文提述的號碼乃本申請表格中各欄的編號。

1 在申請表格欄1簽署及填上日期。只接受親筆簽名。

亦必須註明簽署人的姓名／名稱及代表身份。

如欲使用本申請表格申請香港發售股份，閣下必須為名列於證監會公佈的網上白表服務供應商名單內可以就香港公開發售提供網上白表服務的供應商。

2 在欄2填上閣下欲代表相關申請人申請認購的香港發售股份總數（以數字填寫）。

閣下代其作出申請的相關申請人的申請資料，必須載於連同本申請表格一併遞交的唯讀光碟格式的一個資料檔案內。

3 在欄3填上閣下付款的詳細資料。

閣下必須在本欄註明閣下連同本申請表格隨附的支票數目；及閣下必須在每張支票的背面註明(i) 閣下的網上白表服務供應商編號；及(ii)載有相關申請人的申請詳細資料的資料檔案的檔案編號。

本欄所註明的金額必須與欄2所申請認購的香港發售股份總數應付的金額相同。所有支票及本申請表格連同載有唯讀光碟的密封信封（如有）必須放進蓋上閣下公司印章的信封內。

如以支票繳付股款，該支票必須：

- 為港元支票；
- 不得為期票；
- 由在香港的港元銀行賬戶開出；
- 顯示閣下（或閣下代名人）的賬戶名稱；
- 註明抬頭人為「嘉華銀行（代理）有限公司－思路迪公開發售」；
- 劃線註明「只准入抬頭人賬戶」；及
- 由網上白表服務供應商的授權簽署人簽署。

倘未能符合任何此等規定或倘支票首次過戶不獲兌現，閣下的申請可能會遭拒絕受理。

閣下有責任確保所遞交的支票上的詳細資料與就本申請遞交的唯讀光碟或資料檔案所載的申請詳細資料相同。倘出現差異，本公司及聯席代表有絕對酌情權拒絕接受任何申請。

4 在欄4填上閣下的詳細資料（用正楷填寫）。

閣下必須在本欄填上網上白表服務供應商的名稱、編號及地址。閣下亦必須填寫閣下營業地點的聯絡人士的姓名及電話號碼及（如適用）經紀號碼及加蓋經紀印章。

個人資料收集聲明

此個人資料收集聲明旨在向香港發售股份的申請人及持有人說明有關本公司及香港證券登記分處有關個人資料和香港法例第486章《個人資料（私隱）條例》方面的政策及慣例。

1 收集閣下個人資料的原因

香港發售股份申請人及登記持有人以本身名義申請香港發售股份或轉讓或受讓香港發售股份時或尋求香港證券登記分處的服務時，必須向本公司或其代理及香港證券登記分處提供準確個人資料。

未能提供所要求的資料可能導致閣下的香港發售股份申請被拒或延遲，或本公司或香港證券登記分處無法落實轉讓或以其他方式提供其服務。此舉也可能妨礙或延遲登記或轉讓閣下成功申請的香港發售股份及／或寄發閣下應得的股票。

重要提示：香港發售股份持有人所提供的個人資料如有任何錯誤，須立即通知本公司及香港證券登記分處。

2 用途

閣下的個人資料可以任何方式被使用、持有、處理及／或保存，以作下列用途：

- 處理閣下的申請及退款支票以及電子自動退款指示（如適用），核實是否符合本文件所列的條款及申請程序以及公佈香港發售股份的分配結果；
- 遵守香港及其他地區的所有適用法律及法規；
- 以股份持有人（包括香港結算代理人（如適用））的名義登記新發行股份或轉讓或受讓股份；
- 存置或更新本公司的股東名冊；
- 核實股份持有人的身份；
- 確定股份持有人的受益權利，例如股息、供股及紅股等；

- 分發本公司及其附屬公司的通訊；
- 編製統計資料及股份持有人資料；
- 遵照法律、規則或規例的要求作出披露；
- 透過報章公佈或其他方式披露成功申請人士的身份；

- 披露有關資料以便就權益索償；及
- 與上述有關的任何其他附帶或相關目的及／或使本公司及香港證券登記分處能履行對股份持有人及／或監管機構承擔的責任及／或股份持有人不時同意的任何其他目的。

3 轉交個人資料

本公司及香港證券登記分處所持有關香港發售股份持有人的個人資料將會保密，但本公司及香港證券登記分處可在為達到上述任何目的之必要情況下，向下列任何人士披露、獲取或轉交（無論在香港境內或境外）有關個人資料：

- 本公司委任的代理人，例如財務顧問、收款銀行及主要海外股份過戶登記處；
- （如香港發售股份申請人要求將香港公開發售股份存於中央結算系統）香港結算或香港結算代理人，彼等將會就中央結算系統的運作使用有關個人資料；
- 向本公司或香港證券登記分處提供與其各自業務營運有關的行政、電訊、電腦、付款或其他服務的任何代理、承包商或第三方服務供應商；
- 香港聯交所、證監會及任何其他法定監管機關或政府部門或法例、規則或法規規定的其他機構；及
- 香港發售股份持有人與或擬與之進行交易的任何其他人士或機構，例如彼等的銀行、律師、會計師或股票經紀等。

4 保留個人資料

本公司及香港證券登記分處將按收集個人資料所需的用途保留香港發售股份申請人及持有人的個人資料。無需保留的個人資料將會根據《個人資料（私隱）條例》銷毀或處理。

5 查閱及更正個人資料

香港發售股份持有人有權確定本公司或香港證券登記分處是否持有其個人資料，並有權索取有關該資料的副本並更正任何不準確資料。本公司及香港證券登記分處有權就處理有關要求收取合理費用。所有查閱資料或更正資料的要求應按招股章程「公司資料」一節所披露或不時通知的本公司及香港證券登記分處註冊地址送交公司秘書，或向香港證券登記分處的私隱事務主任提出。

閣下簽署申請表格，即表示同意上述各項。

遞交本申請表格

已填妥的本申請表格，連同相關支票及載有相關唯讀光碟的密封信封，必須於2022年12月7日（星期三）下午四時正之前，送達下列收款銀行：

中信銀行（國際）有限公司
香港鰂魚涌英皇道979號
太古坊德宏大廈4樓